Application of immune checkpoint inhibitors in the treatment of small cell lung cancer / 国际肿瘤学杂志
Journal of International Oncology
;
(12): 747-750, 2021.
Article
in Chinese
| WPRIM
| ID: wpr-930033
ABSTRACT
The emergence of immune checkpoint inhibitors (ICIs) have changed the pattern of anti-tumor therapy and brought new hope to the treatment of small cell lung cancer (SCLC). Currently, ICIs are most widely studied mainly include programmed death-1/ligand-1 and cytotoxic T-lymphocyte antigen-4. Altezumab is recommended for the first-line treatment of extensive SCLC, while pebrizizumab is recommended for the third-line treatment of extensive SCLC. There has been no breakthrough in the second-line and maintenance treatment of SCLC with ICIs.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Journal of International Oncology
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS